Oral doxycycline hyclate — Competitive Intelligence Brief

Oral doxycycline hyclate (Oral doxycycline hyclate) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Tetracycline antibiotic. Area: Infectious Disease.

marketed Tetracycline antibiotic Bacterial 30S ribosomal subunit Infectious Disease Small molecule

Target snapshot

Oral doxycycline hyclate (Oral doxycycline hyclate) — Galderma R&D. Doxycycline hyclate is a tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Oral doxycycline hyclate TARGET	Oral doxycycline hyclate	Galderma R&D	marketed	Tetracycline antibiotic	Bacterial 30S ribosomal subunit
Doxycycline Tablets	Doxycycline Tablets	Yaounde Central Hospital	marketed	Tetracycline antibiotic	Bacterial 30S ribosomal subunit
Doxycycline pre-operatively	Doxycycline pre-operatively	University of Pittsburgh	marketed	Tetracycline antibiotic	Bacterial 30S ribosomal subunit
Amikacin Injection	Amikacin Injection	Murdoch Childrens Research Institute	marketed	Aminoglycoside antibiotic	Bacterial 30S ribosomal subunit
Omadacycline Injection	Omadacycline Injection	Wake Forest University Health Sciences	marketed	Tetracycline antibiotic	Bacterial 30S ribosomal subunit
DoxyPEP	DoxyPEP	Chinese University of Hong Kong	marketed	Tetracycline antibiotic	Bacterial 30S ribosomal subunit
Tobramycin + Dexamethasone	Tobramycin + Dexamethasone	Umm Al-Qura University	marketed	Antibiotic + corticosteroid combination	Bacterial 30S ribosomal subunit (tobramycin); glucocorticoid receptor (dexamethasone)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Tetracycline antibiotic class)

1. OraPharma · 2 drugs in this class
2. Vyne Therapeutics Inc. · 2 drugs in this class
3. Beijing Tiantan Hospital · 1 drug in this class
4. Clinica Universidad de Navarra, Universidad de Navarra · 1 drug in this class
5. Darier · 1 drug in this class
6. Edward Lain, MD · 1 drug in this class
7. Generic (originally Pfizer) · 1 drug in this class
8. Galderma R&D · 1 drug in this class
9. Johns Hopkins University · 1 drug in this class
10. Chinese University of Hong Kong · 1 drug in this class